Medtronic in MRI-safe pacemaker trial:
This article was originally published in Clinica
Executive Summary
Medtronic has begun an international clinical study of what it claims is the "first-ever" pacemaker to be developed and tested specifically for safe use in MRI machines under specified scanning conditions. Its EnRhythm MRI SureScan pacemaker includes modified hardware to minimise the level of energy transmitted through the lead/device connection point. It also includes a feature that can be programmed "on" before an MRI scan to eliminate the impact of MRI-generated electrical noise, which can prevent necessary pacing therapy or cause the device to over-sense and deliver unnecessary pacing therapy. The new study will involve around 350 patients and is expected to last for about 24 months. As for competitors, Pittsford, New York-based Biophan Technologies is aiming to develop biomedical devices capable of safely working with MRI systems.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.